A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.

Inclusion Criteria: 1. Subjects who voluntarily participate in this study and sign the informed consent form. 2. Age from 18 to 70, male or female. 3. Histopathologically/cytologically confirmed or clinically diagnosed with hepatocellular carcinoma (HCC). 4. At least one measurable lesion based on RECIST v1.1. 5. No prior systemic antitumor therapy for HCC. 6. ECOG Performance Status (PS) score of 0-1. 7. Child-Pugh liver function class A. 8. Expected survival at least 3 months. 9. Adequate organ function. 10. Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception. Exclusion Criteria: 1. Known intrahepatic cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma. 2. Other malignancies within the past 5 years or concurrent malignancy. 3. Known history of severe hypersensitivity reaction to any monoclonal antibody. 4. Previous or current central nervous system metastases. 5. Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage. 6. Hypertension that cannot be well controlled with antihypertensive medication. 7. Poorly controlled cardiac symptoms or heart disease. 8. Known hereditary or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency. 9. Arterial thrombotic or embolic events within 6 months before enrollment. 10. Any other condition that, in the investigator's judgment, may affect the study results or lead to premature termination of the study.